GLP-1 therapies key to Australia’s new obesity and CVD treatment guide
The National Heart Foundation released a practical guide for treating obesity and cardiovascular disease, and GLP-1 therapies are key.
The National Heart Foundation released a practical guide for treating obesity and cardiovascular disease, and GLP-1 therapies are key.
Injectable medications originally developed for the treatment of diabetes are also effective for weight loss, and have surged in popularity for this purpose around the world.
New definitions of obesity aim to overcome current limitations that exclude some people from receiving the health care they need, while pushing others towards unnecessary treatments
Around 13 million Australian adults live with overweight or obesity and almost one-third of adults are obese.
Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.